Pharmaceutical formulations and compositions of a selective CXCR2 antagonist or CXCR1 or both CXCR1 and CXCR2 and Methods of using the same for treating inflammatory disorders

摘要

1. An ingredient consisting of a compound or a pharmaceutically acceptable salt and at least one pharmaceutically acceptable precursor chemical, which can release at least 83% of a compound in 5 minutes with a stirrer;Paleta USPII llenado con 900 mL de medio de disoluci n el cual consta de soluci n de lauril sulfato de sodio al 0 5 25 amortiguado con amortiguador de fosfato de sodio a pH de 6 8 a 37 C 0 5 C con la velocidad de paleta fijada It provides for the release of at least 99% of the first compound within 15 minutes. 3. The composition of the first requirement, wherein at least one acceptable precursor chemical is one or more dehumidifiers, one or more polymers, one or more diluents, or one or more diluents. 4. The composition required in Item 1, wherein at least one acceptable precursor chemical is one or more dehumidifiers, one or more polymers, none or more diluents, and one or more diluents. 5. The composition of claim 1,wherein the composition has stable color as assessed by comparing the color of a first sample taken after mixing Compound I, one or more wetting agents, one or more binders, one or more diluents, or one or more disintegrants in a bed fluid with a second sample taken after a dry loss 4% achieved under an inlet air temperature of 70 ° C, and the second sample continues to dry under the inlet air temperature of 70 ° C for at least 80 minutes 6. The composition of Claim 3, wherein one or more wetting agents are present between approximately 0.1 and 8% by weight.